Did Insmed beat or miss consensus estimates last quarter?

What does Insmed do and what are its main business segments?

What were the key takeaways from Insmed’s earnings call?

What is the market's earnings forecast for Insmed next quarter?

What is the revenue and EPS growth rate for Insmed year over year?

What is Insmed's latest dividend and current dividend yield?

What is Insmed's gross profit margin?

What were the key takeaways from Insmed's earnings call?

- **BRINSUPRI Launch Momentum**: $28M in 6 weeks, 2,550 patients, and broad prescriber adoption, despite early-stage uncertainty.
- **Pipeline Progress**: EU brensocatib approval expected in 2025, BiRCh and CEDAR trials on track, and TPIP Phase III启动.
- **Financial Strength**: $1.7B cash, ARIKAYCE guidance raised to $420-430M, and robust pipeline funding.
- **Clinical Catalysts**: ENCORE readout in 2026, BiRCh results in early 2026, and multiple Phase III starts in 2026.


**【CEO Summary Section】**
- Launched BRINSUPRI in the U.S., achieving $28M in net sales in the first 6 weeks, with 2,550 patients and 1,700 prescribers. Emphasized cautious optimism due to early data complexity.
- Highlighted pipeline progress: EU CHMP positive opinion for brensocatib, Phase II BiRCh study in CRS without nasal polyps nearing completion, and CEDAR trial in hidradenitis suppurativa fully enrolled.
- ARIKAYCE revenue up 22% YoY, driven by U.S. and international growth, with potential for expansion into Japan and Europe.

**【CFO Financial Commentary】**
- Raised 2025 ARIKAYCE net revenue guidance to $420-430M (prev. $405-425M), reflecting strong commercial execution.
- Cash position of $1.7B supports BRINSUPRI launch and pipeline investments.
- Q3 2025 R&D and SG&A expenses increased due to BRINSUPRI launch and pipeline expansion.

**【Q&A Highlights】**
- **BRINSUPRI Market Access**: Early ease of access, with focus on 2+ exacerbations criteria; 40% of Q3 sales attributed to channel stocking.
- **BiRCh Study**: 80% powered to detect 0.97 placebo-adjusted treatment effect; data lock expected by early 2026.
- **TPIP Development**: Single Phase III trial for PAH aligned with FDA; Phase III starts in PPF and IPF planned for 2026.
- **HS Pipeline**: CEDAR trial fully enrolled, targeting 20% AN count reduction; 95% powered for 40% reduction.
- **Gene Therapies**: DMD and ALS programs advancing in Phase I, with promising safety profiles.


INSM

INSM fundamentals

You can ask Aime